Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has raised US $200 million by way of private placement of 13% Senior Secured Notes due 2024.
Canadian investors subscribed ##subscriber ONLY content## million of the private placement.
Morgan Stanley & Co. LLC acted as sole placement agent for the transaction. Goodmans LLP acted as Lead Counsel, Morrison & Foerster LLP acted as U.S. counsel and Solomon Harris acted as Cayman Islands counsel for Ironshore.
Based in Cayman Islands, Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS, to optimize the delivery of previously approved drug products.
photo credit: Ironshore Pharmaceuticals & Development
Latest posts by Ted Liu (see all)
- OnDeck to acquire Seer Capital backed Evolocity Financial Group - December 5, 2018
- Fairfax led investment group to privatize AGT for $313M - December 4, 2018
- SLANG Worldwide files for IPO on CSE - November 30, 2018